NFA
ATXS

Nationwide Fund Advisors’s Astria Therapeutics ATXS Stock Holding History

Nationwide Fund Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-63
Closed -$19K – 3266
2016
Q1 		$19K Buy
63
+28
+80% +$9.65K ﹤0.01% 3097
2015
Q4 		$17K Buy
35
+26
+289% +$12.5K ﹤0.01% 3094
2015
Q3 		$4K Buy
+9
New +$6.43K ﹤0.01% 3234

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Nationwide Fund Advisors's ATXS Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Astria Therapeutics (ATXS) in Q2 2016, closing a stake of 63 shares — an estimated $19K sold.

Nationwide Fund Advisors first reported a position in ATXS in Q3 2015 and held it in 3 quarters. The position peaked at $19K in Q1 2016. 27 funds tracked by Wall St. Rank hold ATXS as of Q2 2016.

  • Nationwide Fund Advisors reported no remaining Astria Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Nationwide Fund Advisors sold 63 Astria Therapeutics shares in Q2 2016, an estimated $19K.
  • Nationwide Fund Advisors first reported a position in Astria Therapeutics in Q3 2015 and held it in 3 quarters.
  • Nationwide Fund Advisors's Astria Therapeutics position peaked at $19K in Q1 2016.
  • 27 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.